QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
LON:RENX

Renalytix (RENX) Share Forecast, Price & News

GBX 87.50
0.00 (0.00%)
(As of 06/7/2023 ET)
Compare
Today's Range
85
88.75
50-Day Range
81
95.20
52-Week Range
44
192.49
Volume
8,977 shs
Average Volume
67,281 shs
Market Capitalization
£82.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RENX stock logo

About Renalytix (LON:RENX) Stock

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Receive RENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

RENX Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Renalytix announces a c.$20.3 million private placement
Renalytix Announces Change to Board of Directors
Renalytix Plc (RENX.L)
The Renalytix share price – where next?
See More Headlines

RENX Price History

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
51
Year Founded
N/A

Profitability

Net Income
£-44,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£3.80 million
Cash Flow
GBX 46.86 per share
Book Value
GBX 28 per share

Miscellaneous

Free Float
N/A
Market Cap
£80.65 million
Optionable
Not Optionable
Beta
1.97

Key Executives

  • Mr. James R. McCullough M.B.A. (Age 55)
    CEO & Exec. Director
    Comp: $648k
  • Mr. Fergus Fleming (Age 56)
    CTO & Exec. Director
    Comp: $449k
  • Mr. Thomas H. McLain CPA (Age 64)
    M.B.A, Pres
  • Mr. Oliver James Sterling III
    Chief Financial Officer
  • Ms. Andria Parks-Herrera
    VP of Marketing
  • Ms. Jean M. Casner (Age 64)
    Sr. VP & Chief HR Officer
  • Mr. Baljit Singh
    Head of Clinical Operations
  • Dr. Michael J. Donovan M.D. (Age 69)
    Ph.D., Chief Medical Officer
  • Mr. Salim Hamir F.C.A.
    Company Sec.













RENX Stock - Frequently Asked Questions

How have RENX shares performed in 2023?

Renalytix's stock was trading at GBX 72.50 at the beginning of the year. Since then, RENX shares have increased by 18.6% and is now trading at GBX 86.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Renalytix own?
What is Renalytix's stock symbol?

Renalytix trades on the London Stock Exchange (LON) under the ticker symbol "RENX."

How do I buy shares of Renalytix?

Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Renalytix's stock price today?

One share of RENX stock can currently be purchased for approximately GBX 86.

How much money does Renalytix make?

Renalytix (LON:RENX) has a market capitalization of £80.65 million and generates £3.80 million in revenue each year. The company earns £-44,940,000.00 in net income (profit) each year or GBX (0.64) on an earnings per share basis.

How can I contact Renalytix?

The official website for the company is www.renalytixai.com. The company can be reached via phone at 44 20 3139 2910.

This page (LON:RENX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -